Orphazyme seeks shareholder support in future capital raise

Biotech firm Orphazyme has called an extraordinary general meeting hoping that shareholders will authorize new share issuances.

Photo: Orphazyme/PR

If Orphazyme is to realize its dream of sending drug candidate arimoclomol to market, the biotech company needs more money.

After a string of painful setbacks in 2021 – including the rejection of arimoclomol by the US Food and Drug Administration (FDA) – the company now requires new plans and, more importantly, more financing to continue work.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs